Segall Bryant & Hamill, LLC Vaxcyte, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 184,795 shares of PCVX stock, worth $9 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
184,795
Previous 180,239
2.53%
Holding current value
$9 Million
Previous $5.86 Million
13.6%
% of portfolio
0.09%
Previous 0.09%
Shares
8 transactions
Others Institutions Holding PCVX
# of Institutions
316Shares Held
132MCall Options Held
493KPut Options Held
162K-
Janus Henderson Group PLC London, X013.1MShares$638 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$600 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$583 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$484 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$405 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.89B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...